Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
PLoS One ; 3(10): e3315, 2008 Oct 02.
Artigo em Inglês | MEDLINE | ID: mdl-18830402

RESUMO

BACKGROUND: Cowpea Mosaic Virus (CPMV) is increasingly being used as a nanoparticle platform for multivalent display of molecules via chemical bioconjugation to the capsid surface. A growing variety of applications have employed the CPMV multivalent display technology including nanoblock chemistry, in vivo imaging, and materials science. CPMV nanoparticles can be inexpensively produced from experimentally infected cowpea plants at high yields and are extremely stable. Although CPMV has not been shown to replicate in mammalian cells, uptake in mammalian cells does occur in vitro and in vivo. Thus, inactivation of the virus RNA genome is important for biosafety considerations, however the surface characteristics and chemical reactivity of the particles must be maintained in order to preserve chemical and structural functionality. METHODOLOGY/PRINCIPAL FINDINGS: Short wave (254 nm) UV irradiation was used to crosslink the RNA genome within intact particles. Lower doses of UV previously reported to inactivate CPMV infectivity inhibited symptoms on inoculated leaves but did not prohibit systemic virus spread in plants, whereas higher doses caused aggregation of the particles and an increase in chemical reactivity further indicating broken particles. Intermediate doses of 2.0-2.5 J/cm(2) were shown to maintain particle structure and chemical reactivity, and cellular binding properties were similar to CPMV-WT. CONCLUSIONS: These studies demonstrate that it is possible to inactivate CPMV infectivity while maintaining particle structure and function, thus paving the way for further development of CPMV nanoparticles for in vivo applications.


Assuntos
Comovirus/efeitos da radiação , Nanopartículas , Raios Ultravioleta , Inativação de Vírus , Comovirus/patogenicidade
2.
Vaccine ; 19(27): 3661-70, 2001 Jun 14.
Artigo em Inglês | MEDLINE | ID: mdl-11395200

RESUMO

A vaccine based upon a recombinant plant virus (CPMV-PARVO1), displaying a peptide derived from the VP2 capsid protein of canine parvovirus (CPV), has previously been described. To date, studies with the vaccine have utilized viable plant chimaeric particles (CVPs). In this study, CPMV-PARVO1 was inactivated by UV treatment to remove the possibility of replication of the recombinant plant virus in a plant host after manufacture of the vaccine. We show that the inactivated CVP is able to protect dogs from a lethal challenge with CPV following parenteral immunization with the vaccine. Dogs immunized with the inactivated CPMV-PARVO1 in adjuvant displayed no clinical signs of disease and shedding of CPV in faeces was limited following CPV challenge. All immunized dogs elicited high titres of peptide-specific antibody, which neutralized CPV in vitro. Levels of protection, virus shedding and VP2-specific antibody were comparable to those seen in dogs immunized with the same VP2- peptide coupled to keyhole limpet hemocyanin (KLH). Since plant virus-derived vaccines have the potential for cost-effective manufacture and are not known to replicate in mammalian cells, they represent a viable alternative to current replicating vaccine vectors for development of both human and veterinary vaccines.


Assuntos
Comovirus/imunologia , Infecções por Parvoviridae/prevenção & controle , Parvovirus Canino/imunologia , Proteínas Recombinantes/uso terapêutico , Proteínas Virais/uso terapêutico , Vacinas Virais/uso terapêutico , Sequência de Aminoácidos , Animais , Capsídeo/uso terapêutico , Proteínas do Capsídeo , Comovirus/efeitos da radiação , Doenças do Cão/prevenção & controle , Doenças do Cão/virologia , Cães , Esquemas de Imunização , Dados de Sequência Molecular , Infecções por Parvoviridae/mortalidade , Infecções por Parvoviridae/veterinária , Parvovirus Canino/efeitos da radiação , Raios Ultravioleta , Vacinas de Produtos Inativados/uso terapêutico , Vacinas Sintéticas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...